

# Joshua Richter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2525869/publications.pdf>

Version: 2024-02-01

55  
papers

1,358  
citations

566801

15  
h-index

360668

35  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1827  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 129-132.	0.2	1
2	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11
3	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	2.2	44
4	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	7
5	What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. <i>Targeted Oncology</i> , 2022, 17, 383-405.	1.7	7
6	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 31-45.	1.0	7
7	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072098707.	1.1	10
8	Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522199553.	0.5	1
9	Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e284-e289.	0.2	9
10	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826.	2.0	9
11	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e470-e476.	0.2	12
12	Management of patients with difficult-to-treat multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2089-2105.	1.1	1
13	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.2	10
14	Anti-body building: The exercise of advancing immune based myeloma therapies. <i>Blood Reviews</i> , 2021, 48, 100789.	2.8	2
15	Bispecific Antibodies in Multiple Myeloma: Present and Future. <i>Blood Cancer Discovery</i> , 2021, 2, 423-433.	2.6	43
16	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Review of Hematology</i> , 2021, 14, 1099-1114.	1.0	10
17	Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E430-E433.	2.0	4
18	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8

#	ARTICLE	IF	CITATIONS
19	B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	1.1	24
20	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53
21	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	3
22	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021, 138, 2704-2704.	0.6	6
23	Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature. <i>Blood</i> , 2021, 138, 457-457.	0.6	1
24	Real-World Multiple Myeloma Treatment Patterns By Patient Characteristics and Outcomes in the United States. <i>Blood</i> , 2021, 138, 4114-4114.	0.6	0
25	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. <i>Science Advances</i> , 2021, 7, eabg9551.	4.7	49
26	Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1658-1658.	0.6	9
27	Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease. <i>Blood</i> , 2021, 138, 3759-3759.	0.6	0
28	Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. <i>Blood</i> , 2021, 138, 4969-4969.	0.6	0
29	Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. <i>Frontiers in Oncology</i> , 2021, 11, 819127.	1.3	10
30	Recapturing disease response: A phase 2 study of carfilzomib 56â€‰%mg/m <sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27â€‰%mg/m <sup>2</sup> . <i>American Journal of Hematology</i> , 2020, 95, E51-E54.	2.0	0
31	Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 100, 3057-3060.	0.8	2
32	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020, 13, 94.	6.9	107
33	Bispecifics, trispecifics, and other novel immune treatments in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 264-271.	0.9	40
34	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
35	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020, 13, 943-958.	1.0	16
36	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2208-2215.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e734-e751.	0.2	2
38	Selinexor in relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093062.	1.1	35
39	Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date. <i>Seminars in Oncology</i> , 2020, 47, 155-164.	0.8	11
40	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e341-e344.	0.2	2
41	Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 407-414.	0.2	8
42	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 632-636.e1.	0.2	31
43	Variation in the Treatment of Multiple Myeloma in the Real World. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
44	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. <i>Blood</i> , 2020, 136, 6-7.	0.6	8
45	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
46	Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies. <i>Cancer Journal (Sudbury,)</i> Tj ETQq0 0 0 0 r gBT /Overlock 10 T	1.6	0
47	A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1881-1891.	1.3	2
48	Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. <i>Blood</i> , 2019, 134, 1779-1779.	0.6	1
49	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
50	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2616.	2.2	44
51	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 693-702.	0.2	5
52	Walking on myeloma. <i>Blood</i> , 2018, 132, 1724-1724.	0.6	2
53	E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3216-3216.	0.6	6
54	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598.	0.6	17

#	ARTICLE	IF	CITATIONS
55	Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma. Blood, 2018, 132, 59-59.	0.6	4